Retatrutide is a medication that is currently under investigation for its potential to treat obesity and type 2 diabetes. It’s a novel drug that works by targeting and activating specific receptors involved in appetite regulation and metabolic processes.

Retatrutide belongs to a class of drugs known as dual or triple agonists, which means it can activate multiple types of receptors to achieve its effects. Specifically, Retatrutide is a combination agonist of the GLP-1, GIP, and glucagon receptors. These receptors are involved in regulating glucose metabolism, appetite, and energy expenditure.

Research suggests that Retatrutide may offer significant benefits in weight management and glucose control compared to existing treatments. However, it’s still in the clinical trial phase, so its long-term effectiveness and safety profile are not yet fully established